iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021

NEXT STORY
OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
PREV STORY
Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update

author_avatar
NASDAQ Market News

Vaxil Granted First U.S. Patent for Its Cancer Immunotherapy Antibody Platform

NESS-ZIONA, ISRAEL--(Marketwired - March 01, 2018) - VAXIL BIO LTD. (TSX VENTURE: VXL), an ...

author_avatar
NASDAQ Market News

TYME Presentation at ESMO Reported 100% of Current Prostate Cancer Patients Have Demonstrated a Reduction in Circulating Tumor Cells, Most Becoming Undetectable

- Results suggest SM-88 may help avoid or delay more intensive treatments, such as ...

author_avatar
NASDAQ Market News